



## Figure A-1. Risk Difference Meta-Analyses of Total VTE and All-Cause Mortality: Dabigatran 220 vs Enoxaparin – All Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 06 Total VTE and all cause mortality - Risk difference  
 Outcome: 08 Dabigatran 220 - random - all




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 06 Total VTE and all cause mortality - Risk difference  
 Outcome: 07 Dabigatran 220 - fixed - all




## Figure A-2. Risk Difference Meta-Analyses of Total VTE and All-Cause Mortality: Dabigatran 220 vs Enoxaparin – European Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 06 Total VTE and all cause mortality - Risk difference  
 Outcome: 06 Dabigatran 220 - random - 2 studies (25, 48)




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 06 Total VTE and all cause mortality - Risk difference  
 Outcome: 05 Dabigatran 220 - fixed - 2 studies (25, 48)




### Figure A-3. Risk Difference Meta-Analyses of Total VTE and All-Cause Mortality: Dabigatran 220 vs Enoxaparin – Knee Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 06 Total VTE and all cause mortality - Risk difference  
 Outcome: 12 Dabigatran 220 - random - 2 studies (24, 25)




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 06 Total VTE and all cause mortality - Risk difference  
 Outcome: 11 Dabigatran 220 - fixed - 2 studies (24, 25)




## Figure A-4. Risk Difference Meta-Analyses of Major VTE and VTE-related Death: Dabigatran 220 vs Enoxaparin – All Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 10 Major VTE and VTE related death - Risk difference  
 Outcome: 08 Dabigatran 220 - random - all




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 10 Major VTE and VTE related death - Risk difference  
 Outcome: 07 Dabigatran 220 - fixed - all




## Figure A-5. Risk Difference Meta-Analyses of Major VTE and VTE-related Death: Dabigatran 220 vs Enoxaparin – European Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 10 Major VTE and VTE related death - Risk difference  
 Outcome: 06 Dabigatran 220 - random - 2 studies (25, 48)




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 10 Major VTE and VTE related death - Risk difference  
 Outcome: 05 Dabigatran 220 - fixed - 2 studies (25, 48)




## Figure A-6. Risk Difference Meta-Analyses of Major VTE and VTE-related Death: Dabigatran 220 vs Enoxaparin – Knee Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 10 Major VTE and VTE related death - Risk difference  
 Outcome: 12 Dabigatran 220 - random - 2 studies (24, 25)




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 10 Major VTE and VTE related death - Risk difference  
 Outcome: 11 Dabigatran 220 - fixed - 2 studies (24, 25)




## Figure A-7. Risk Difference Meta-Analyses of Major Bleed: Dabigatran 220 vs Enoxaparin – All Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 07 Major Bleed - Risk difference  
 Outcome: 08 Dabigatran 220 - random - all




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 07 Major Bleed - Risk difference  
 Outcome: 07 Dabigatran 220 - fixed - all




## Figure A-8. Risk Difference Meta-Analyses of Major Bleed: Dabigatran 220 vs Enoxaparin – European Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 07 Major Bleed - Risk difference  
 Outcome: 06 Dabigatran 220 - random - 2 studies (25, 48)



Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 07 Major Bleed - Risk difference  
 Outcome: 05 Dabigatran 220 - fixed - 2 studies (25, 48)






## Figure A-9. Risk Difference Meta-Analyses of Major Bleed: Dabigatran 220 vs Enoxaparin – Knee Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials

Comparison: 07 Major Bleed - Risk difference


Outcome: 12 Dabigatran 220 - random - 2 studies (24, 25)



Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials


Comparison: 07 Major Bleed - Risk difference

Outcome: 11 Dabigatran 220 - fixed - 2 studies (24, 25)




## Figure A-10. Risk Difference Meta-Analyses of Clinically Relevant Bleed: Dabigatran 220 vs Enoxaparin – All Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 08 Clinically Relevant Bleed - Risk difference  
 Outcome: 08 Dabigatran 220 - random - all




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 08 Clinically Relevant Bleed - Risk difference  
 Outcome: 07 Dabigatran 220 - fixed - all




## Figure A-11. Risk Difference Meta-Analyses of Clinically Relevant Bleed: Dabigatran 220 vs Enoxaparin – European Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 08 Clinically Relevant Bleed - Risk difference  
 Outcome: 06 Dabigatran 220 - random - 2 studies (25, 48)




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 08 Clinically Relevant Bleed - Risk difference  
 Outcome: 05 Dabigatran 220 - fixed - 2 studies (25, 48)




## Figure A-12. Risk Difference Meta-Analyses of Clinically Relevant Bleed: Dabigatran 220 vs Enoxaparin – Knee Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 08 Clinically Relevant Bleed - Risk difference  
 Outcome: 12 Dabigatran 220 - random - 2 studies (24, 25)




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 08 Clinically Relevant Bleed - Risk difference  
 Outcome: 11 Dabigatran 220 - fixed - 2 studies (24, 25)




## Figure A-13. Risk Difference Meta-Analyses of Clinically Relevant / Minor Bleed: Dabigatran 220 vs Enoxaparin – All Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 09 Clinically Relevant / Minor Bleed - Risk difference  
 Outcome: 08 Dabigatran 220 - random - all




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 09 Clinically Relevant / Minor Bleed - Risk difference  
 Outcome: 07 Dabigatran 220 - fixed - all




## Figure A-14. Risk Difference Meta-Analyses of Clinically Relevant / Minor Bleed: Dabigatran 220 vs Enoxaparin – European Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 09 Clinically Relevant / Minor Bleed - Risk difference  
 Outcome: 06 Dabigatran 220 - random - 2 studies (25, 48)




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 09 Clinically Relevant / Minor Bleed - Risk difference  
 Outcome: 05 Dabigatran 220 - fixed - 2 studies (25, 48)




## Figure A-15. Risk Difference Meta-Analyses of Clinically Relevant / Minor Bleed: Dabigatran 220 vs Enoxaparin – Knee Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 09 Clinically Relevant / Minor Bleed - Risk difference  
 Outcome: 12 Dabigatran 220 - random - 2 studies (24, 25)




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 09 Clinically Relevant / Minor Bleed - Risk difference  
 Outcome: 11 Dabigatran 220 - fixed - 2 studies (24, 25)




## Figure A-16. Risk Difference Meta-Analyses of Total VTE and All-Cause Mortality: Dabigatran 150 vs Enoxaparin – All Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 06 Total VTE and all cause mortality - Risk difference  
 Outcome: 04 Dabigatran 150 - random - all




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 06 Total VTE and all cause mortality - Risk difference  
 Outcome: 03 Dabigatran 150 - fixed - all






## Figure A-17. Risk Difference Meta-Analyses of Total VTE and All-Cause Mortality: Dabigatran 150 vs Enoxaparin – European Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 06 Total VTE and all cause mortality - Risk difference  
 Outcome: 02 Dabigatran 150 - random - 2 studies (25, 48)




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 06 Total VTE and all cause mortality - Risk difference  
 Outcome: 01 Dabigatran 150 - fixed - 2 studies (25, 48)




## Figure A-18. Risk Difference Meta-Analyses of Total VTE and All-Cause Mortality: Dabigatran 150 vs Enoxaparin – Knee Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 06 Total VTE and all cause mortality - Risk difference  
 Outcome: 10 Dabigatran 150 - random - 2 studies (24, 25)




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 06 Total VTE and all cause mortality - Risk difference  
 Outcome: 09 Dabigatran 150 - fixed - 2 studies (24, 25)




## Figure A-19. Risk Difference Meta-Analyses of Major VTE and VTE-related Death: Dabigatran 150 vs Enoxaparin – All Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 10 Major VTE and VTE related death - Risk difference  
 Outcome: 04 Dabigatran 150 - random - all




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 10 Major VTE and VTE related death - Risk difference  
 Outcome: 03 Dabigatran 150 - fixed - all




## Figure A-20. Risk Difference Meta-Analyses of Major VTE and VTE-related Death: Dabigatran 150 vs Enoxaparin – European Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 10 Major VTE and VTE related death - Risk difference  
 Outcome: 02 Dabigatran 150 - random - 2 studies (25, 48)




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 10 Major VTE and VTE related death - Risk difference  
 Outcome: 01 Dabigatran 150 - fixed - 2 studies (25, 48)




## Figure A-21. Risk Difference Meta-Analyses of Major VTE and VTE-related Death: Dabigatran 150 vs Enoxaparin – Knee Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 10 Major VTE and VTE related death - Risk difference  
 Outcome: 10 Dabigatran 150 - random - 2 studies (24, 25)



Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 10 Major VTE and VTE related death - Risk difference  
 Outcome: 09 Dabigatran 150 - fixed - 2 studies (24, 25)




## Figure A-22. Risk Difference Meta-Analyses of Major Bleed: Dabigatran 150 vs Enoxaparin – All Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials

Comparison: 07 Major Bleed - Risk difference


Outcome: 04 Dabigatran 150 - random - all



Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials


Comparison: 07 Major Bleed - Risk difference

Outcome: 03 Dabigatran 150 - fixed - all




## Figure A-23. Risk Difference Meta-Analyses of Major Bleed: Dabigatran 150 vs Enoxaparin – European Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 07 Major Bleed - Risk difference  
 Outcome: 02 Dabigatran 150 - random - 2 studies (25, 48)




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 07 Major Bleed - Risk difference  
 Outcome: 01 Dabigatran 150 - fixed - 2 studies (25, 48)




## Figure A-24. Risk Difference Meta-Analyses of Major Bleed: Dabigatran 150 vs Enoxaparin – Knee Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 07 Major Bleed - Risk difference  
 Outcome: 10 Dabigatran 150 - random - 2 studies (24, 25)




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 07 Major Bleed - Risk difference  
 Outcome: 09 Dabigatran 150 - fixed - 2 studies (24, 25)






## Figure A-25. Risk Difference Meta-Analyses of Clinically Relevant Bleed: Dabigatran 150 vs Enoxaparin – All Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 08 Clinically Relevant Bleed - Risk difference  
 Outcome: 04 Dabigatran 150 - random - all




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 08 Clinically Relevant Bleed - Risk difference  
 Outcome: 03 Dabigatran 150 - fixed - all




## Figure A-26. Risk Difference Meta-Analyses of Clinically Relevant Bleed: Dabigatran 150 vs Enoxaparin – European Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 08 Clinically Relevant Bleed - Risk difference  
 Outcome: 02 Dabigatran 150 - random - 2 studies (25, 48)




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 08 Clinically Relevant Bleed - Risk difference  
 Outcome: 01 Dabigatran 150 - fixed - 2 studies (25, 48)




## Figure A-27. Risk Difference Meta-Analyses of Clinically Relevant Bleed: Dabigatran 150 vs Enoxaparin – Knee Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 08 Clinically Relevant Bleed - Risk difference  
 Outcome: 10 Dabigatran 150 - random - 2 studies (24, 25)




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 08 Clinically Relevant Bleed - Risk difference  
 Outcome: 09 Dabigatran 150 - fixed - 2 studies (24, 25)




## Figure A-28. Risk Difference Meta-Analyses of Clinically Relevant / Minor Bleed: Dabigatran 150 vs Enoxaparin – All Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 09 Clinically Relevant / Minor Bleed - Risk difference  
 Outcome: 04 Dabigatran 150 - random - all




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 09 Clinically Relevant / Minor Bleed - Risk difference  
 Outcome: 03 Dabigatran 150 - fixed - all




## Figure A-29. Risk Difference Meta-Analyses of Clinically Relevant / Minor Bleed: Dabigatran 150 vs Enoxaparin – European Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 09 Clinically Relevant / Minor Bleed - Risk difference  
 Outcome: 02 Dabigatran 150 - random - 2 studies (25, 48)




Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 09 Clinically Relevant / Minor Bleed - Risk difference  
 Outcome: 01 Dabigatran 150 - fixed - 2 studies (25, 48)



## Figure A-30. Risk Difference Meta-Analyses of Clinically Relevant / Minor Bleed: Dabigatran 150 vs Enoxaparin – Knee Trials

Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 09 Clinically Relevant / Minor Bleed - Risk difference  
 Outcome: 10 Dabigatran 150 - random - 2 studies (24, 25)



Review: BI-VTE, Phase 2, Meta Analyses, 3 dabigatran trials  
 Comparison: 09 Clinically Relevant / Minor Bleed - Risk difference  
 Outcome: 09 Dabigatran 150 - fixed - 2 studies (24, 25)

